KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to -$248.1 million.

  • Regeneron Pharmaceuticals' Net Cash Flow rose 501.33% to $497.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.4 million, marking a year-over-year increase of 437.42%. This contributed to the annual value of -$248.1 million for FY2024, which is 34.92% up from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' Net Cash Flow is -$248.1 million, which was up 34.92% from -$381.2 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Net Cash Flow ranged from a high of $690.8 million in FY2021 and a low of -$381.2 million during FY2023.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Net Cash Flow value was -$248.1 million (recorded in 2024), while the average stood at -$136.0 million.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Net Cash Flow spiked by 284.41% in 2020 and then slumped by 272.25% in 2023.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Net Cash Flow stood at $577.0 million in 2020, then rose by 19.72% to $690.8 million in 2021, then slumped by 67.96% to $221.3 million in 2022, then tumbled by 272.25% to -$381.2 million in 2023, then skyrocketed by 34.92% to -$248.1 million in 2024.